Literature DB >> 16327315

The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.

Deenan Pillay1, Krishnan Bhaskaran, Suzanne Jurriaans, Maria Prins, Bernard Masquelier, Francois Dabis, Robert Gifford, Claus Nielsen, Court Pedersen, Claudia Balotta, Giovanni Rezza, Marta Ortiz, Carmen de Mendoza, Claudia Kücherer, Gabriele Poggensee, John Gill, Kholoud Porter.   

Abstract

BACKGROUND: Transmission of drug-resistant HIV-1 is well recognized. However, the impact of such transmission on natural history of infection remains unknown.
METHODS: Three hundred HIV-1-infected, antiretroviral-naive individuals, recruited between 1987 and 1993, and with resistance tests undertaken within 18 months of infection were assessed. We estimated the impact of transmitted drug resistance (TDR) on subsequent CD4 cell count decline in the absence of treatment. We also used Kaplan-Meier methods to assess the response to antiretroviral therapy based on the number of active drugs utilized (according to genotypic resistance results).
RESULTS: Infection with any form of drug-resistant HIV-1 was associated with a steeper decline of CD4 cell count over the first year of infection. Estimated rates of decline in the first year were 5.0 [95% confidence interval (CI), 2.8-7.3] and 1.7 (95% CI, 0.8-2.6) radicalCD4 cells per year for TDR and no TDR, respectively (P = 0.005). For an individual at a CD4 cell count of 500 cells/microl at seroconversion, these rates correspond to a CD4 cell loss of 199 and 73 cells/microl, respectively, in the first year. Thereafter we found no evidence of a difference in the rate of CD4 cell decline (P = 0.32). Initiation of HAART after calendar year 2000, but not number of active drugs, was associated with improved responses.
CONCLUSIONS: The impact of transmitted HIV-1 drug resistance on CD4 cell decline is time dependent, with greater rates of decline in the first year following infection. We found no evidence of a longer term effect of TDR on natural history of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16327315     DOI: 10.1097/01.aids.0000196172.35056.b7

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  36 in total

1.  Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

Authors:  Sara Gianella; Wayne Delport; Mary E Pacold; Jason A Young; Jun Yong Choi; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

3.  An enantioselective enzymatic desymmetrization route to hexahydro-4H-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Anindya Sarkar
Journal:  Tetrahedron Lett       Date:  2017-07-03       Impact factor: 2.415

4.  Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule.

Authors:  Christopher B Hurt
Journal:  Antivir Ther       Date:  2011

5.  Identification of Novel Resistance-Related Polymorphisms in HIV-1 Subtype C RT Connection and RNase H Domains from Patients Under Virological Failure in Brazil.

Authors:  Maria F M Barral; Arielly K P Sousa; André F Santos; Celina M Abreu; Amilcar Tanuri; Marcelo A Soares
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-27       Impact factor: 2.205

6.  Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund Project.

Authors:  M A Pando; M Gómez-Carrillo; M Vignoles; A E Rubio; M S dos Ramos Farias; M Vila; D Rossi; G Ralón; R Marone; E Reynaga; J Sosa; O Torres; M Maestri; M M Avila; H Salomón
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-23       Impact factor: 2.205

7.  Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.

Authors:  Arun K Ghosh; Bruno D Chapsal; Abigail Baldridge; Melinda P Steffey; D Eric Walters; Yasuhiro Koh; Masayuki Amano; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2010-12-31       Impact factor: 7.446

8.  Baseline clinical characteristics, antiretroviral therapy use, and viral load suppression among HIV-positive young men of color who have sex with men.

Authors:  Lisa B Hightow-Weidman; Karen Jones; Gregory Phillips; Amy Wohl; Thomas P Giordano
Journal:  AIDS Patient Care STDS       Date:  2011-06-28       Impact factor: 5.078

9.  Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.

Authors:  Arun K Ghosh; Sandra Gemma; Abigail Baldridge; Yuan-Fang Wang; Andrey Yu Kovalevsky; Yashiro Koh; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2008-09-11       Impact factor: 7.446

10.  Transmission cluster of multiclass highly drug-resistant HIV-1 among 9 men who have sex with men in Seattle/King County, WA, 2005-2007.

Authors:  Susan E Buskin; Giovanina M Ellis; Gregory G Pepper; Lisa M Frenkel; Steven A Pergam; Geoffrey S Gottlieb; Carrie Horwitch; Jeffrey F Olliffe; Karen Johnson; Peter Shalit; Corinne Heinen; Margot Schwartz; Robert W Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.